1. Short title This Act may be cited as the Medicaid Drug Decisions Transparency Act . 2. Ownership or investment interest transparency for health care providers and others (a) In general Section 1128G of the Social Security Act ( 42 U.S.C. 1320a–7h ) is amended— (1) in subsection (b)— (A) in paragraph (1)(A), by striking $10,000 and inserting $20,000 ; (B) in paragraph (1)(B), by striking $150,000 and inserting $300,000 ; (C) in paragraph (2)(A), by striking $100,000 and inserting $200,000 ; and (D) in paragraph (2)(B), by striking $1,000,000 and inserting $2,000,000 ; (2) in subsection (d)(2), by adding at the end the following sentence: Beginning with calendar year 2021, such report shall include a separate summary of the information submitted under subsection (a) during the preceding year with respect to the covered recipients described in clause (vii) of subsection (e)(6)(A). ; and (3) in subsection (e)(6)(A), by adding at the end the following: (vi) A pharmacist (as defined in section 804(a)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 384(a)(2) ). (vii) An individual or entity with decision-making authority over the formulary or preferred drug list of a State plan (or a waiver of a plan) under title XIX, including an individual or entity that participates in the establishment of such a drug formulary or preferred drug list or in the drug utilization review process for such a plan or waiver, such as a member of a State drug use review board described in section 1927. . (b) Effective date The amendments made by this section shall take effect on January 1, 2020, and shall apply to information required to be submitted under section 1128G of the Social Security Act ( 42 U.S.C. 1320a–7h ) on or after such date. 3. State drug use review board membership transparency Section 1927(g)(3)(B) of the Social Security Act ( 42 U.S.C. 1396r–8(g)(3)(B) ) is amended— (1) by redesignating clauses (i) through (iv) as subclauses (I) through (IV) and moving such subclauses (as so redesignated) 2 ems to the right